In-vitro Characterization of Solrikitug, A Differentiated Anti-TSLP Antibody, Provides Distinct Epitope Binding Profile and Superior Potency Compared to Tezepelumab

作者
K. Komori,Michael Lore,H. Postlethwaite,Volkan Manga,Lisa Wittmer,Hector G. Ortega
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:211 (Supplement_1): A1393-A1393 被引量:3
标识
DOI:10.1164/ajrccm.2025.211.abstracts.a1393
摘要

Abstract Introduction: Thymic stromal lymphopoietin (TSLP) is an alarmin expressed by epithelial cells in the lung, skin and gastrointestinal tract upon inflammation and tissue damage. As an upstream initiator of inflammatory cascades, TSLP activates dendritic and mast cells, and promotes Type 2 inflammation. Solrikitug is a fully humanized anti-TSLP monoclonal antibody in development for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis. To understand potential advantages compared to tezepelumab, head-to-head in vitro studies assessing binding affinity, epitope identification, and functional inhibition were performed. Methods: Solrikitug and tezepelumab binding affinities, on-rates, and off-rates, were determined by surface plasmon resonance. Competitive TSLP binding was assessed by biolayer interferometry with sequential antibody binding to TSLP. Functional inhibition was evaluated by TSLP-dependent proliferation of Ba/F3 cells, and assessment of TARC expression by ELISA following stimulation of healthy volunteer PBMC with TSLP for 5 days. Results: Solrikitug and tezepelumab bind to TSLP with similar affinities (11 pM vs. 16 pM, respectively), on-rates and off-rates. Competitive binding assays demonstrated that solrikitug and tezepelumab did not compete with each other for TSLP binding, indicating the two antibodies recognize different epitopes on TSLP. Solrikitug was a more potent inhibitor of TSLP-dependent cell proliferation and TARC expression compared to tezepelumab. Conclusions: Solrikitug is a potent anti-TSLP monoclonal antibody in development for the treatment of respiratory and gastrointestinal inflammatory diseases. Solrikitug demonstrates unique epitope binding compared to the approved in class comparator, tezepelumab. Moreover, solrikitug demonstrates potentially best-in-class functional inhibition. The differentiated profile of solrikitug compared to tezepelumab supports the potential of solrikitug for the treatment of patients with severe respiratory conditions such as asthma and COPD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘刘溜完成签到 ,获得积分10
刚刚
刚刚
英子爱阿亮完成签到,获得积分10
刚刚
刚刚
李爱国的应助被selena采纳,获得10
1秒前
兮尔完成签到,获得积分10
1秒前
1秒前
爆米花的应助被乎乎采纳,获得10
1秒前
1秒前
啊熙发布了新的文献求助30
2秒前
Tsct完成签到,获得积分10
2秒前
kai完成签到,获得积分20
2秒前
尊敬店员发布了新的文献求助40
2秒前
舒适香露发布了新的文献求助10
3秒前
热情的坤完成签到,获得积分10
3秒前
华仔的应助被Lily采纳,获得10
4秒前
程朗发布了新的文献求助30
4秒前
天天快乐的应助被兮尔采纳,获得10
5秒前
传奇3的应助被Man采纳,获得10
5秒前
苗条元霜完成签到,获得积分10
5秒前
Czz发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
jichao完成签到,获得积分10
6秒前
Bio发布了新的文献求助10
7秒前
小f完成签到,获得积分10
7秒前
7秒前
8秒前
亲爱的桃乐茜完成签到 ,获得积分10
8秒前
9秒前
9秒前
9秒前
9秒前
1176915210完成签到,获得积分10
10秒前
10秒前
10秒前
酷波er的应助被舒适香露采纳,获得10
10秒前
11秒前
安静葵阴发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183241
求助须知:如何正确求助?哪些是违规求助? 9572493
关于积分的说明 21826218
捐赠科研通 7780115
什么是DOI,文献DOI怎么找? 3433982
关于科研通互助平台的介绍 2558103
邀请新用户注册赠送积分活动 2480192